Precision BioSciences, Inc. (DTIL) News
Follow Precision BioSciences, Inc. (DTIL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Precision Bio doses first patient in Phase 1/2 FUNCTION-DMD trial
DTIL Precision Biosciences dosed the first patient in August in its Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD for Duchenne muscular dystrophy, targeting up to 60% of patients.
EQUITY | Aug 24, 2026, 10:37 AM UTC
M
Precision BioSciences begins dosing in Phase 1/2 FUNCTION-DMD study
Precision BioSciences says it has commenced dosing in its Phase 1/2 FUNCTION-DMD study.
EQUITY | Aug 24, 2026, 10:03 AM UTC
L
DTIL Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Miles
DTIL Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
EQUITY | Jul 27, 2026, 11:01 AM UTC
L
Precision Biosciences Activates Second Clinical Site At Washington University School Of Medicine As It Begins The FUNCTION-DMD Clinical Tria
Also in its updated corporate deck, the Company announced activation of a second clinical site at Washington University School of Medicine in St. Louis, Missouri as it commences the FUNCTION-DMD clinical trial evaluating
EQUITY | Jul 01, 2026, 11:27 AM UTC